Machine Learning
Machine Learning
In conventional computing AI training takes a lot of time and computational resources. Even with the latest hardware, training an AI to a level that can be considered sufficient takes an incredibly long time and even then, inevitably, there will be mistakes made by the AI, hence why it is only considered “sufficient”. But with a quantum computer’s superposition it can essentially carry out operations simultaneously.
This mindset of simultaneous computation is not new, Graphics Processing Units (GPUs) have an architecture that is conducive to this simultaneous compute mindset, relative to classical CPUs. GPUs have many “cores” that are specialised and are a lot less versatile than CPU cores but since AI training is essentially just repeating a relatively simple task over and over, GPUs have been the first choice in hardware for AI training for a long time. However, due to the nature of classical bits they can only be improved by adding more cores; long-term this is infeasible considering how much harder it is to make smaller process nodes.
Drug Discovery
Research and development is so fundamental to pharmaceutical companies that they spend an average of 15 percent of their sales on R&D
6. The molecular formations required in drug development are so small that quantum phenomena affect them, so quantum computing could be incredibly useful in the Computer-Aided Drug Design (CADD) process.
It is anticipated that quantum computing will be able to predict and simulate the structure, properties, and behaviour (or reactivity) of these molecules more effectively than conventional computing can.
3 Using conventional computers for increasing the accuracy of the molecular simulations has an exponential increase in computational resources; the emergence of quantum computers has the potential to remedy the fact it is expensive for a conventional computer to try to simulate quantum systems; such as molecules.
Pharma is already making use of machine learning to speed up and improve the drug development process, but considering machine learning will take a great leap forward when quantum computers can be used for it, pharma is positioned to be one of the prime beneficiaries of the advent of quantum computers.
In conclusion:
The pace of drug discovery took a leap with the aid of machine learning but with the advent of quantum computers on the horizon it is clear that the pharma industry is in for a qualitative transformation to its drug development cycle.
References
With thanks to Alimul Karim, Intern